Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chang Ik Choi

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
Therapeutics and Clinical Risk Management|February 9, 2018
Prediction of emergence agitation using withdrawal reaction following rocuronium injection in preschool-aged patients undergoing inguinal herniorrhaphy: a preliminary exploratory observational trialDae Hee Kim, Go Un Roh, Young Bok Lee, et al.
European Journal of Clinical Pharmacology|September 25, 2010
Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjectsJung-Woo Bae, Chang-Ik Choi, Jin-Hee Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 28, 2012
Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174Jung-Woo Bae, Chang-Ik Choi, Hye-In Lee, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
Coixol and Sinigrin from <i>Coix lacryma-jobi</i> L. and <i>Raphanus sativus</i> L. Promote Fat Browning in 3T3-L1 AdipocytesSeung Min Choi, Sung Ho Lim, Ho Seon Lee, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
Fat Browning Effects of Catalpol and Rhoifolin from <i>Rehmannia glutinosa</i> (Gaertn.) and <i>Lonicera japonica</i> (Thunb.) in 3T3-L1 Adipocytes via the β3-AR Signaling PathwaySeung Min Choi, Sung Ho Lim, Ho Seon Lee, et al.
Archives of Pharmacal Research|December 28, 2024
Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypesChang-Keun Cho, Pureum Kang, Choon-Gon Jang, et al.
Archives of Pharmacal Research|April 25, 2024
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetineChang-Keun Cho, Pureum Kang, Choon-Gon Jang, et al.
Archives of Pharmacal Research|April 25, 2023
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjectsPureum Kang, Chang-Keun Cho, Choon-Gon Jang, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatinHye-In Lee, Chang-Ik Choi, Joon-Ho Sa, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 11, 2012
Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical applicationChang-Ik Choi, Jung-In Park, Hye-In Lee, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
Therapeutics and Clinical Risk Management|February 9, 2018
Prediction of emergence agitation using withdrawal reaction following rocuronium injection in preschool-aged patients undergoing inguinal herniorrhaphy: a preliminary exploratory observational trialDae Hee Kim, Go Un Roh, Young Bok Lee, et al.
European Journal of Clinical Pharmacology|September 25, 2010
Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjectsJung-Woo Bae, Chang-Ik Choi, Jin-Hee Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 28, 2012
Effects of CYP2C9*1/*3 and *1/*13 on the pharmacokinetics of losartan and its active metabolite E-3174Jung-Woo Bae, Chang-Ik Choi, Hye-In Lee, et al.
Pharmaceuticals (Basel, Switzerland)|December 31, 2025
Coixol and Sinigrin from <i>Coix lacryma-jobi</i> L. and <i>Raphanus sativus</i> L. Promote Fat Browning in 3T3-L1 AdipocytesSeung Min Choi, Sung Ho Lim, Ho Seon Lee, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2026
Fat Browning Effects of Catalpol and Rhoifolin from <i>Rehmannia glutinosa</i> (Gaertn.) and <i>Lonicera japonica</i> (Thunb.) in 3T3-L1 Adipocytes via the β3-AR Signaling PathwaySeung Min Choi, Sung Ho Lim, Ho Seon Lee, et al.
Archives of Pharmacal Research|December 28, 2024
Effects of fluconazole on the pharmacokinetics of celecoxib and its carboxylic acid metabolite in different CYP2C9 genotypesChang-Keun Cho, Pureum Kang, Choon-Gon Jang, et al.
Archives of Pharmacal Research|April 25, 2024
PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetineChang-Keun Cho, Pureum Kang, Choon-Gon Jang, et al.
Archives of Pharmacal Research|April 25, 2023
Effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy subjectsPureum Kang, Chang-Keun Cho, Choon-Gon Jang, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 21, 2014
Ursodeoxycholic acid, an inhibitor of hepatocyte nuclear factor 1α, did not increase the systemic exposure of pitavastatinHye-In Lee, Chang-Ik Choi, Joon-Ho Sa, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 11, 2012
Determination of tolperisone in human plasma by liquid chromatography/tandem mass spectrometry for clinical applicationChang-Ik Choi, Jung-In Park, Hye-In Lee, et al.
Pageof 7